Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Share-based Compensation for 14 consecutive years, with $30.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 25.0% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $142.9 million (down 11.27% YoY), while the FY2025 annual figure was $153.0 million, down 3.16% from the prior year.
• Share-based Compensation fell to $30.0 million in Q1 2026 per RARE's latest filing, from $37.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $41.6 million in Q3 2024 and bottomed at $1.6 million in Q1 2022.
• Historically, Share-based Compensation has averaged $30.3 million across 5 years, with a median of $35.8 million in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 93.49% — and 2025, when it jumped 1335.75%.
• Ultragenyx Pharmaceutical's Share-based Compensation stood at $29.4 million in 2022, then increased by 14.23% to $33.5 million in 2023, then gained by 19.69% to $40.1 million in 2024, then slipped by 7.09% to $37.3 million in 2025, then slipped by 19.55% to $30.0 million in 2026.
• Business Quant data shows RARE's Share-based Compensation at $30.0 million in Q1 2026, $37.3 million in Q4 2025, and $37.0 million in Q3 2025.